Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 38, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.nano.2021.102447
Keywords
MSC derived exosome; Cochlea explant; Hearing loss; Cisplatin; HSP70
Funding
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI19C1334]
Ask authors/readers for more resources
In this study, human MSC-derived exosomes were evaluated for their efficacy in protecting against cisplatin-induced ototoxic hearing loss. Results showed that incubation of cochlear explants with MSC-derived exosomes reduced drug toxicity in auditory hair cells, supporting the potential therapeutic benefits of stem cell-derived exosomes in clinical applications.
Therapeutics based on stem cell technology, including stem cell-derived exosomes, have emerged in recent years for the treatment of what were otherwise considered incurable diseases. In this study, we evaluated the efficacy of human MSC-derived exosomes for protection against cisplatin induced ototoxic hearing loss. Incubation of cochlear explants with MSC-derived exosomes prior to addition of cisplatin induced a reduction in cisplatin-induced drug toxicity in auditory hair cells but not when the exosomes were introduced simultaneously with or after cisplatin. The delivery of MSC-derived exosomes to cochlear explants was confirmed by the increasing protein levels of the exosome markers CD63 and HSP70 to reduce apoptosis. These results were consistent with those from a model in which MSC-derived exosomes protect auditory hair cells from cisplatin-induced drug toxicity in an ex vivo cochlear explant model and support future studies into the therapeutic benefits of stem cell-derived exosomes in clinical applications. (C) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available